United States

Cumberland Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor for Coronavirus Patients

Lead Product(s): Ibuprofen

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration March 31, 2020

Details:

The collaboration aims at providing hospitals and clinics that use Caldolor® injection for the treatment of COVID-19 patients easy access financial arrangements to combat medical requirements.

ADMA Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option

Lead Product(s): Human Immune Globulin

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Morgan Stanley

Deal Size: $94.6 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 24, 2020

Details:

ADMA intends to use the net proceeds from this offering (i) for the procurement of raw materials for the manufacturing of BIVIGAM and ASCENIV.

ADMA Biologics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

ADMA Biologics Announces Proposed $75 Million Public Offering

Lead Product(s): Human Immune Globulin

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Morgan Stanley

Deal Size: $82.3 million Upfront Cash: Undisclosed

Deal Type: Public Offering February 06, 2020

Details:

ADMA intends to use the net proceeds to procure raw materials for the production of BIVIGAM and ASCENIV, to support their marketing and other corporate purposes.

Aimmune Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Aimmune Announces $200 Million Equity Investment by Nestle

Lead Product(s): Peanut (Arachis hypogaea) Allergen-dnfp

Therapeutic Area: Immunology

Highest Development Status: Approved Product Type: Large molecule

Partner/Sponsor/Collaborator: Nestle Health Science

Deal Size: $473.0 million Upfront Cash: Undisclosed

Deal Type: Investment February 05, 2020

Details:

Nestle Health Science's investment in Aimmune is intended to help assure PALFORZIA’s longer-term commercial success and allow Aimmune to continue making progress in food allergy treatments.

Find

Find drug development pipeline and deal Updates information

A collaboration with SCORR Marketing

Product Type

Companies

Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor for Coronavirus Patients

ADMA Biologics

ADMA Biologics Announces Closing of Full Exercise of Underwriters’ Option

ADMA Biologics

ADMA Biologics Announces Proposed $75 Million Public Offering

Aimmune Therapeutics

Aimmune Announces $200 Million Equity Investment by Nestle